Market News AIOpen the app

Cingulate Inc. shared its third quarter results and plans to resubmit its drug application by early 2027.

ResultsRead the original at globenewswire.com
Good for CING

Cingulate has about $23.2 million in cash for work into mid-2027 and has substantially completed manufacturing work requested by the FDA. It expects to resubmit CTx-1301’s application between December 2026 and January 2027; the stated funding period is limited, but the progress supports Cingulate’s outlook.

CING · Cingulate Inc.

AI read · Good for CING

The AI's read

Completing the FDA-requested manufacturing work brings CTx-1301 closer to another review. The application has not yet been resubmitted, so that step remains ahead. The cash can support regulatory work and launch preparation, but the stated funding period is limited.

Get alerts for CING

Follow Cingulate Inc. (CING) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CING
Free on the App Store and Google Play, or on the web.